{"groups":[{"description":"Drug: pomalidomide Taken orally once a day\n\nDrug: dexamethasone Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15\n\nDrug: rituximab Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15\n\npomalidomide: Taken orally once a day\n\ndexamethasone: Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15\n\nrituximab: Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15","id":"FG000","title":"Pomalidomide, Dexamethasone, Rituximab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Adverse Event"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"A total of 7 participants were recruited at the DFCI medical clinic between 9/22/2010 and 4/3/2012."}